Please login to the form below

Not currently logged in
Email:
Password:

stomach cancer

This page shows the latest stomach cancer news and features for those working in and with pharma, biotech and healthcare.

CHMP turns down BMS’ Opdivo/Yervoy for kidney cancer

CHMP turns down BMS’ Opdivo/Yervoy for kidney cancer

Withdrawals. Meanwhile, applications to extend the use of Opdivo to include the treatment of stomach cancer, and for Sutent to treat patients at high risk of kidney cancer returning after surgery, ... precursor acute lymphoblastic leukaemia (ALL)

Latest news

  • Vyriad inks immunotherapy alliance with Merck/Pfizer Vyriad inks immunotherapy alliance with Merck/Pfizer

    Merck KGaA and its avelumab partner Pfizer have agreed to test the cancer immunotherapy alongside an oncolytic virus therapy developed by US biotech Vyriad. ... cell lung cancer and also had a knockback in third-line stomach cancer last year.

  • Merck/Pfizer’s cancer immunotherapy latecomer hits a snag Merck/Pfizer’s cancer immunotherapy latecomer hits a snag

    Merck/Pfizer’ s cancer immunotherapy latecomer hits a snag. Bavencio fails a key lung cancer trial. ... It’s not the first setback for Bavencio, which failed a trial in third-line stomach cancer treatment last year, and in that indication too the

  • Merck and Pfizer’s PD-L1 drug Bavencio flunks phase III trial Merck and Pfizer’s PD-L1 drug Bavencio flunks phase III trial

    Fails late-stage stomach cancer study. Already playing catch-up in the immuno-oncology market, Merck KGaA and Pfizer’s hopes for their PD-L1 inhibitor Bavencio just took a knock ... These include Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers

  • Mylan gets first biosimilar Herceptin OK from FDA Mylan gets first biosimilar Herceptin OK from FDA

    The biosimilar – developed by Mylan and Biocon and called Ogivri (trastuzumab-dkst) – has been approved by the FDA for HER2-positive breast or metastatic stomach cancer, the same indications as Herceptin ... This is especially important when it comes

  • Keytruda adds stomach cancer to growing list of US approvals Keytruda adds stomach cancer to growing list of US approvals

    Keytruda adds stomach cancer to growing list of US approvals. FDA clears the drug as a third-line option after chemotherapy. ... The company notes that Keytruda is the first PD-1 inhibitor to be approved for stomach cancer in the US and will be used for

More from news
Approximately 4 fully matching, plus 27 partially matching documents found.

Latest Intelligence

  • Country report: The healthcare market in China Country report: The healthcare market in China

    Leading public health issues include HIV/AIDS, cancer (stomach, lung, liver, cervical, breast) and heart diseases. ... Approximately 400, 000 patients are newly diagnosed with stomach cancer annually, with a rising prevalence in the number of younger

  • Country report: The healthcare market in Japan Country report: The healthcare market in Japan

    3. Coronary heart disease. 4. Lung cancer. 5. Stomach cancer. 6. ... The largest therapeutic category is Renin-angiotensin system agents (antihypertensive), followed by anti-neoplastics (cancer drugs).

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

Shanghai
Biopharma's Future: Made in China
The world’s second biggest pharma market is entering a new growth phase – but meeting its needs takes investment and expertise...
Solaris Health looks at the gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....

Infographics